Pioglitazone hydrochloride

GDC-0927 (SRN-927) is a potent, non-steroidal, orally bioavailable, selective estrogen receptor antagonistIn VivoGDC-0927 is a novel, potent, non-steroidal, orally bioavailable, selective ER antagonist/ER degrader (SERD) that induces tumor

GDC-0927 (SRN-927) is a potent, non-steroidal, orally bioavailable, selective estrogen receptor antagonistIn VivoGDC-0927 is a novel, potent, non-steroidal, orally bioavailable, selective ER antagonist/ER degrader (SERD) that induces tumor

Application Givinostat hydrochloride hydrate has been used as a histone deacetylase inhibitor to test its effect on the human immunodeficiency virus reactivation in CD4 + T-cell model. Biochem/physiol Actions Givinostat (ITF2357) is a

Application Givinostat hydrochloride hydrate has been used as a histone deacetylase inhibitor to test its effect on the human immunodeficiency virus reactivation in CD4 + T-cell model. Biochem/physiol Actions Givinostat (ITF2357) is a

GNE-502 is an orally active and potent degrader for estrogen receptor ( ER ). GNE-502 can be used for the research of breast cancerIn VivoGNE-502 (10 and 100 mg/kg: p.o.) possesses sufficient oral exposure to be tested in a WT MCF7 tumor xenograft

GNE-502 is an orally active and potent degrader for estrogen receptor ( ER ). GNE-502 can be used for the research of breast cancerIn VivoGNE-502 (10 and 100 mg/kg: p.o.) possesses sufficient oral exposure to be tested in a WT MCF7 tumor xenograft

GNE-502 is an orally active and potent degrader for estrogen receptor ( ER ). GNE-502 can be used for the research of breast cancerIn VivoGNE-502 (10 and 100 mg/kg: p.o.) possesses sufficient oral exposure to be tested in a WT MCF7 tumor xenograft

GPR40 agonist 6 (Compound 7a) is a potent and selective free fatty acid receptor 1 ( FFAR1 or GPR40 ) agonist with an EC 50 of 0.058 μMIn VitroGPR40 agonist 6 (Compound 7a) shows a very favorable ADME profile, and shows no significant inhibition of

GPR40 agonist 6 (Compound 7a) is a potent and selective free fatty acid receptor 1 ( FFAR1 or GPR40 ) agonist with an EC 50 of 0.058 μMIn VitroGPR40 agonist 6 (Compound 7a) shows a very favorable ADME profile, and shows no significant inhibition of

GPR40 agonist 6 (Compound 7a) is a potent and selective free fatty acid receptor 1 ( FFAR1 or GPR40 ) agonist with an EC 50 of 0.058 μMIn VitroGPR40 agonist 6 (Compound 7a) shows a very favorable ADME profile, and shows no significant inhibition of

GPR40 agonist 6 (Compound 7a) is a potent and selective free fatty acid receptor 1 ( FFAR1 or GPR40 ) agonist with an EC 50 of 0.058 μMIn VitroGPR40 agonist 6 (Compound 7a) shows a very favorable ADME profile, and shows no significant inhibition of

GPR40 agonist 6 (Compound 7a) is a potent and selective free fatty acid receptor 1 ( FFAR1 or GPR40 ) agonist with an EC 50 of 0.058 μMIn VitroGPR40 agonist 6 (Compound 7a) shows a very favorable ADME profile, and shows no significant inhibition of